Jpmorgan Chase & CO Alx Oncology Holdings Inc Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALXO
# of Institutions
101Shares Held
39.7MCall Options Held
134KPut Options Held
17.4K-
Ven Bio Partners LLC San Francisco, CA9.7MShares$14.3 Million14.51% of portfolio
-
Tang Capital Management LLC San Diego, CA4.2MShares$6.18 Million0.65% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.03MShares$5.93 Million1.07% of portfolio
-
Redmile Group, LLC San Francisco, CA3.84MShares$5.64 Million0.46% of portfolio
-
Black Rock Inc. New York, NY2.69MShares$3.95 Million0.0% of portfolio
About ALX ONCOLOGY HOLDINGS INC
- Ticker ALXO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,747,100
- Market Cap $59.9M
- Description
- ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...